Oticon Medical Announces Launch of Ponto 5 SuperPower

31 March 2022

First 65 dB Processor with Open Sound Experience and No Audible Feedback


For the first time, the revolutionary open sound experience is available in a bone anchored SuperPower sound processor. With a fitting range up to 65 dB HL BC, the Ponto 5 SuperPower delivers powerful sound to help more people get the right solution for their hearing loss. And it is packed with breakthrough features, including industry-first feedback prevention, all in the world’s smallest SuperPower device.

Today, Oticon Medical announced the launch of the new Ponto 5 SuperPower sound processor, adding to the groundbreaking Ponto 5 family. Introducing full SuperPower strength in the smallest SuperPower device ever available, the Ponto 5 SuperPower also delivers a huge leap in sound processor technology – including a patented feature to prevent audible feedback – along with a sleek cosmetic design.


It’s a great milestone on our mission of empowering all users with the best possible sound experience


One of the most exciting breakthroughs in the industry, the patented OpenSound Optimizer™ technology in the Ponto 5 SuperPower cracks the code of how to prevent feedback. It works by detecting and preventing audible feedback from occurring, rather than managing feedback by reducing amplification. This enables audiologists to fit users with up to 5 dB extra stable gain without compromising on the dynamics of sound.1

In addition, pioneering OpenSound Navigator™ technology gives users access to their full 360° soundscape, rather than simply focusing on speech as traditional technologies do. This provides users with greater focus and awareness of their surroundings and has been confirmed in a study to significantly improve speech understanding.*2

This combination of unique features works seamlessly across listening environments to deliver breakthrough fuller sound, without the risk of audible feedback.**1

Commenting on the launch, Søren Nielsen, CEO of Demant and acting President of Oticon Medical, says, “I’m incredibly proud that we were able to develop technology that can prevent feedback without decreasing gain. Now, offering this and other BrainHearing™ technologies in a SuperPower means we can provide access to more sound for a wider range of users. It’s a great milestone on our mission of empowering all users with the best possible sound experience.”

As part of the Ponto 5 family, the new Ponto 5 SuperPower is also designed with premium details such as easy connectivity and streaming, the Oticon RemoteCare platform for access to care from anywhere, as well as the state-of-the-art reliability, durability and product quality that have become synonymous with Ponto.


Because sound matters

Oticon Medical is a global company in implantable hearing solutions, dedicated to bringing the power of sound to people at every stage of life. As part of the Demant Group, a global leader in hearing healthcare with more than 16,500 people in over 30 countries and users benefitting from our products and solutions in more than 130 countries, we have access to one of the world’s strongest research and development teams, the latest technological advances and insights into hearing care. Our competencies span more than a century of innovations in sound processing and decades of pioneering experience in hearing implant technology. We work collaboratively with patients, physicians and hearing care professionals to ensure that every solution we create is designed with users’ needs in mind. We have a strong passion to provide innovative solutions and support that enhance quality of life and help people live full lives – now and in the future. Because we know how much sound matters.



†When measured on Ponto 5 SuperPower relative to Ponto 3 SuperPower
*Increased speech understanding when comparing performance with OpenSound Navigator ON relative to OpenSound Navigator OFF.
** For prescribed fittings, according to best practice and during normal use.
1 Data on file at Oticon Medical
2 Data on file at Oticon Medical – Clinical study BC109